I-RJMPDRN® REC kunye ne-Arelastin® ze-Uniproma zifakwe kuluhlu olufutshane lweMbasa yeZithako ezisebenzayo eBalaseleyo kwi-In-Cosmetics Latin America ngo-2025

Iimbono ezili-13

Ikhethini livukileIzinto zokuthambisa zaseLatin America 2025(nge-23–24 kaSeptemba, eSão Paulo), kwaye i-Uniproma iqala ukudlala kakuhle kwi-Yima J20Kulo nyaka, siyazingca ngokubonisa izinto ezimbini ezintsha ezisandul’ ukuveliswa—I-RJMPDRN® RECkwayeI-Arelastin®— zombini ezi zikhethwe kuluhlu oluphezuluIbhaso leZithako eziSebenzayo eliBalaseleyo, nto leyo ephawula isiganeko esibalulekileyo kuhambo lwethu lwe-R&D.

I-RJMPDRN® RECyi-PDRN yokuqala ehlabathini yesalmon ephinda-phindayo. Ngenxa yezakhono ezibalaseleyo zokuvuselela ulusu kunye nokulwa nokwaluphala, imele umlinganiselo omtsha wezinto zobuhle eziqhutywa yi-biotechnology.I-Arelastin®Okwangoku, yi-elastin eyi-100% edibeneyo eyenziwe ngumntu, eyakhiwe ngesakhiwo esiyingqayizivele se-β-spiral. Izifundo zeklinikhi zibonisa ukuba inokubonelela ngophuculo olubonakalayo ekuqineni kolusu kunye nokuthamba kwalo kwiveki nje enye.

Ukuqatshelwa kwezi zinto zintsha kubonisa ukuzinikela kwe-Uniproma ekuqhubeleni phambili inkqubela phambili yesayensi kwicandelo lobuhle kunye nokhathalelo lomntu. Ngokusebenzisa itekhnoloji edibeneyo, sijolise ekuboneleleni ngezisombululo ezisebenzayo, ezikhuselekileyo, nezizinzileyo ezinika amandla abenzi beemveliso zokhathalelo lolusu lwesizukulwana esilandelayo.

Kuyo yonke le mboniso, iqela lethu lisebenzisana namaqabane ehlabathi, abaphandi, kunye nabaqulunqi ukuze batshintshiselane ngolwazi baze baphonononge intsebenziswano. Njengoko i-Uniproma iphambili, ijonge phambili ekuqhubekeni nomsebenzi wayo wokubumba ikamva lesayensi yobuhle kwihlabathi liphela.

Samkela ngokufudumeleyo bonke abatyeleliYima J20ukuze sifumane izinto ezintsha esizifumene kuluhlu lweembasa ezikhethiweyo kwaye siqhagamshelane neqela lethu ubuso ngobuso.

20250924-173521

I-Uniproma-In-Cosmetics Latin America 2025(1)

I-Uniproma-In-Cosmetics Latin America 2025(2)


Ixesha leposi: Sep-24-2025